Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
WALTHAM, Mass., Oct. 20, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
-
WALTHAM, Mass., Oct. 13, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that its...
-
Notable results from Genentech/Roche Phase II trial are featured in conference's official press program T-DM1 utilizes ImmunoGen's Targeted Antibody Payload (TAP) technology with the...
-
WALTHAM, Mass., Sept. 22, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody...
-
WALTHAM, Mass., Aug. 31, 2011 (GLOBE NEWSWIRE) -- ImmunoGen, Inc. (Nasdaq:IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and...